Firefly Neuroscience, Inc. AIFF
2.01
0.82
68.91%
as of 25 Sep
- Market cap
- $18.7M
- P/E
- 0.0×
Follow AIFF
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
50.17 | 9.59 | 22.33 | 13.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.40) | (6.07) | (18.16) | (14.23) | |
P/B ratio |
4.07 | 1.43 | 4.19 | 1.70 | |
Price to Tangible BV |
10.96 | 6.84 | 14.47 | 2.86 | |
EV/Sales |
45.20 | 7.56 | 20.63 | 8.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.65) | (1.05) | (4.28) | (2.30) | |
EV/FCF |
(4.46) | (1.02) | (4.11) | (2.20) | |
Quick Ratio |
1.66 | 1.04 | 1.35 | 4.49 | |
Current Ratio |
2.00 | 1.43 | 1.82 | 4.87 | |
Net Debt/EBITDA |
1.77 | 1.17 | 1.59 | 4.79 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.15 | 0.14 | 0.11 | |
Operating CF/Net income |
0.56 | 0.66 | 0.93 | 0.88 | |
Capex/Depreciation |
(0.41) | (0.15) | (1.29) | (0.89) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
97.42% | 110.68% | 87.42% | 102.14% | |
Selling, General and Administrative Expense of Revenue |
585.57% | 516.50% | 372.58% | 331.13% | |
Intangible Assets out of Total Assets |
0.49 | 0.58 | 0.55 | 0.36 | |
Share Based Compensation of Revenue |
27.58% | 136.41% | 119.59% | 69.26% | |
Graham Net Nets |
0.07 | 0.11 | 0.06 | 0.33 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(71.82%) | (204.55%) | (28.90%) | (48.76%) | |
Free Cash Flow Yield |
(20.18%) | (77.24%) | (22.46%) | (29.46%) | |
Revenue per Share |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF per Share |
(0.11) | (0.15) | (0.12) | (0.08) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.15) | (0.12) | (0.09) | |
Cash per Share |
0.32 | 0.22 | 0.19 | 0.45 | |
Shareholders Equity per Share |
0.72 | 0.61 | 0.52 | 0.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.72 | 0.61 | 0.52 | 0.71 | |
Free Cash Flow |
(1.57) | (1.83) | (2.01) | (1.79) | |
Working Capital |
2.71 | 1.21 | 2.01 | 8.13 | |
Capital Expenditures |
(0.09) | (0.02) | (0.06) | (0.04) | |
Net Current Asset Value |
2.68 | 1.19 | 1.99 | 8.12 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.22 | 0.06 | 0.12 | 0.08 | |
Net Profit Margin |
(680.15%) | (659.95%) | (431.75%) | (385.99%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.49 | 0.14 | 0.16 | 0.14 | |
Average Payables |
1.36 | 1.58 | 1.47 | 1.19 | |
Average Inventory |
— | — | — | 0.09 | |
Average Assets |
8.86 | 7.54 | 11.64 | 15.85 | |
Average Common Equity |
6.22 | 3.63 | 6.81 | 13.38 |
Columns are period end dates